Discrepancy between the in vitro and in vivoeffects of murine mesenchymal stem cells on T-cell proliferation and collagen-induced arthritis

Table 1 Cumulative incidence and mean scores of arthritis in mice treated with wild-type or IFN-γR KO DBA/1 MSCs or with C57BL/6 MSCs^a

Experiment	Route^b	Administration time^c	Treatment^d	Cumulative incidence^e, fraction (percentage)	Score of arthritis, mean ± SEM^{e, f}
1	i.v.	Day -1	Control	4/8 (50%)	2.0 ± 0.9
			Wild-type MSCs	1/2 (50%)	1.5 ± 1.5
			IFN-γR KO MSCs	3/7 (43%)	1.6 ± 1.0
			T_reg cells	2/8 (25%)	0.4 ± 0.3
2	i.v.	Day 16	Control	4/10 (40%)	1.3 ± 0.7
			Wild-type MSCs	6/8 (75%)	2.1 ± 0.6
			IFN-γR KO MSCs	4/10 (40%)	0.8 ± 0.4
3	i.v.	Days 16 and 23	Control	5/10 (50%)	3.0 ± 1.4
			Wild-type MSCs	5/9 (56%)	2.5 ± 0.9
			IFN-γR KO MSCs	5/10 (50%)	2.0 ± 0.8
4	i.p.	Days 16, 23, and 30	Control	7/8 (88%)	5.1 ± 1.5
			Wild-type MSCs	6/7 (86%)	5.3 ± 1.2
			IFN-γR KO MSCs	8/9 (89%)	4.6 ± 1.6
5	i.p.	Days 16, 23, and 30	Control	7/11 (64%)	1.3 ± 0.5
			C57BL/6 MSCs	8/11 (73%)	2.7 ± 1.2

^aMice were immunized with collagen type II in complete Freund's adjuvant on day 0 and were treated^b either intravenously (i.v.) or intraperitoneally (i.p.) on the indicated time points^c with wild-type mesenchymal stem cells (MSCs), interferon-gamma receptor knockout (IFN-γR KO) MSCs, C57BL/6 MSCs, regulatory T (T_reg) cells, or phosphate-buffered saline (control group)^d. ^eArthritic incidence and score of arthritis in all groups at day 35. ^fArthritic scores were not significantly different between control treatment and treatment with wild-type or IFN-γR KO DBA/1 MSCs or C57BL/6 MSCs or with T_reg cells. SEM, standard error of the mean.

ISSN: 1478-6362